Module

Debate: Are Noninvasive Tests Ready to Replace Liver Biopsy?

Source: Hepatitis Annual Update 2006

Debate: Are Noninvasive Tests Ready to Replace Liver Biopsy?


Program Director: Emmet B. Keeffe, MD, MACP

Faculty:

Nezam H. Afdhal, MD, FRCPIMitchell L. Shiffman, MD
  • Nezam H. Afdhal, MD, FRCPI
  • Mitchell L. Shiffman, MD

CME CREDIT INFORMATION

Release Date: 06/30/06

Expiration Date: 06/29/07


Physicians: maximum of 1.5 AMA PRA Category 1 Credits

Registered Nurses: 1.7 Nursing CE credits

Pharmacists: 1.4 contact hours (0.14 CEUs)

Status: Please log in to view status


Begin the Module

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the role of liver biopsy and the noninvasive tests available (and in development) for the diagnosis of liver fibrosis and inflammation
  • Review the latest data supporting the use of liver biopsy or noninvasive tests, including data on risk, sensitivity, and specificity
  • Discuss the limitations of liver biopsy and noninvasive tests

Topics covered include:

  • In Favor of the Use of Noninvasive Tests
    • Liver Biopsy
    • Noninvasive Techniques
      • Radiology
      • Hepatic Elastography
      • Serum Markers of Fibrosis
        • Indirect Markers: Assessing Liver Function
        • Direct Markers: Assessing Fibrogenesis
    • A Clinical Algorithm for Assessing Liver Fibrosis
  • In Favor of the Use of Liver Biopsy
    • Indications for Liver Biopsy: Biopsy Diagnosis of Different Liver Diseases
    • Biopsy to Assess Severity of Liver Disease and When to Initiate Therapy
    • Biopsy to Assess Response to Therapy
    • Noninvasive Markers to Assess Liver Disease
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.